Drug intelligence / Profile preview

Personalized Idiotype Vaccine

Development stage: Unknown
Lead developer: Bayer
Modality: Vaccines & Immunotherapeutics
Administration: Subcutaneous, Intramuscular, Intradermal

Overview

The Personalized Idiotype Vaccine is a therapeutic vaccine developed by Bayer Innovation GmbH for the treatment of Non-Hodgkin's Lymphoma (NHL). This vaccine is designed to be personalized, utilizing idiotype proteins specific to a patient's tumor. These idiotype proteins are produced using Bayer's magnICON® plant-based expression system and are coupled with Keyhole Limpet Hemocyanin (KLH), supplied by Stellar Biotechnologies, which serves as an immunogenic carrier to enhance the immune response. The vaccine was in Phase 1 clinical trials for NHL.

Targets

Id (Tumor-specific idiotype immunoglobulin)

Beyond the preview

Go deeper on Personalized Idiotype Vaccine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Personalized Idiotype Vaccine.

Explore the full profile